Former HHS official calls for FDA to control Rx drug costs
Slater made the comments in an editorial she wrote appearing in the Jan. 20 edition of the New England Journal of Medicine (NEJM)
The FDA's "expertise must be brought to bear in the control of surging drug costs," she wrote.
Slater commented that the FDA "must evolve beyond satisfying the appetite of industry for faster approval of drugs."
Slater was HHS assistant secretary for health between 2002 and 2003 after working for 19 years at Merck.